Systemic light chain amyloidosis (AL) Program in Pharmaceutical Benefits Scheme (PBS) 012-22121931
Expand allThis document outlines details of PBS-subsidised daratumumab for patients with systemic light chain amyloidosis.
AL and listing dates
Systemic light chain amyloidosis is a rare disease that occurs when a protein called amyloid builds up in organs.
Listing date: daratumumab - 1 January 2023.
For more details, see Written Authority Required Drugs.
The Resources page contains:
- application forms
- contact details
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing and National Demand Allocation (PaNDA)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)